Painkiller may also fight bacteria in PCA pumps

NCT ID NCT07285759

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This lab study tested whether levobupivacaine, a local anesthetic used in patient-controlled analgesia (PCA) pumps, can kill Staphylococcus aureus bacteria. Researchers mixed the drug at two common concentrations with bacteria in a lab model and counted how many bacteria survived. The goal is to see if the anesthetic itself might help prevent infections in patients using these pain pumps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Levobupivacaine

What this could lead to

If levobupivacaine shows strong antibacterial effects, it could help reduce infection risk in patients using PCA pumps for pain relief.

What could go wrong

This is a small lab study, not a human trial. Results may not translate to real-world use, and the effect might be too weak to matter clinically.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS AUREUS BACTERIAL CONTAMINATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

staphylococcal infection staphylococcus aureus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.